Serum concentrations of prostate-specific antigen (PSA) before and after the treatment in patients with prostate cancer
DOI:
https://doi.org/10.5902/2236583443968Keywords:
Prostate neoplasms, Early diagnosis, Prostate-specific antigen.Abstract
Introduction: Prostate cancer is the second most prevalent neoplasm in men in Brazil. The prevention is recommended from 45 years for men with a family history of prostate cancer and from the age of 65 to the others. The aim of this study was to evaluate serum prostate-specific antigen (PSA) levels in patients diagnosed with prostate cancer before and after the treatment. Methods: This is a descriptive, cross-sectional and retrospective study, of a quantitative approach, in which were analyzed patients diagnosed with prostate cancer in the city of Parnaíba, Piauí, Brazil. Results: Twenty-nine patients were included, with a mean age of 76.6 years. According to the results of PSA dosing before (PSA1) and after (PSA2) the treatment, 19 (65.5%) patients presented a decrease in PSA2 values. Surgical treatment was required in nine (31%) patients. Radiotherapy was performed in 23 (79.3%) patients and six (20.7%) were undergoing treatment with hormone therapy. No patient underwent chemotherapy. Conclusion: The results of the present study demonstrated declines in PSA values after the treatment for prostate cancer. However, it is necessary to spread the knowledge and raise the awareness of the male population about the importance of early detection to a successfully prognosis and also to increase the men demand for health services and prevention.
Downloads
References
Bacelar Júnior AJ; Menezes CS, Barbosa CA, Freitas JBS, Silva GG, Vaz JPS, et al. Câncer de próstata: métodos de diagnóstico, prevenção e tratamento. Brazilian Journal of Surgery and Clinical Research. 2015; 10(3): 40-46.
Sousa WS. Avaliação epidemiológica dos resultados laboratoriais de PSA realizados para diagnóstico de câncer de próstata de pacientes atendidos em um Hospital Universitário de Minas Gerais. [Trabalho de Conclusão de Curso]. Juiz de Fora: Faculdade de Farmácia, Universidade de Juiz de Fora; 2016.
Instituto Nacional do Câncer José Alencar Gomes da Silva/Ministério da Saúde. Câncer de próstata: vamos falar sobre isso?. 2017. [acesso 2019 Nov. 15]. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//cartilha_cancer_prostata_2017.pdf
Damião R, Figueiredo RT, Dornas MC, Lima DS, Koschorke MAB. Câncer de próstata. Revista Hospital Universitário Pedro Ernesto. 2015; 14(1): 80-86. doi: 10.12957/rhupe.2015.17931
Olivieri M. Representações sócias de homens sobre o exame preventivo do câncer de próstata. [Dissertação de Mestrado]. Sorocaba: Faculdade de Ciências Médicas e da Saúde, Pontifícia Universidade Católica de São Paulo; 2016.
Gomes R, Moreira MCN, Nascimento EF, Rebello LEFS, Couto MT, Schraiber LB. Os homens não vêm! Ausência e/ou invisibilidade masculina na atenção primária. Ciência & Saúde Coletiva. 2011; 16(Supl. 1):983-992. http://dx.doi.org/10.1590/S1413-81232011000700030
SANTOS, Marceli de Oliveira. Estimativa 2018: incidência de câncer no Brasil. Revista Brasileira de Cancerologia, v. 64, n. 1, p. 119-120, 2018.
La Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naive men. The Journal of urology. 2015; 94(1): 65-72. https://doi.org/10.1016/j.juro.2015.01.091
Modesto AAD, Lima RLB, D’Angelis AC, Augusto DK. A not-so-blue November: debating screening of prostate cancer and men’s health. Interface (Botucatu). 2018; 22(64):251-62. http://dx.doi.org/10.1590/1807-57622016.0288
Lima AP, Lini EV, Giacomazzi RB, Dellani MP, Portella MR, Doring M. Prevalence and factors associated with the performance of prostate cancer screening in the elderly: a population-based study. Revista Brasileira de Geriatria e Gerontologia. 2018; 21(1): 53–59. http://dx.doi.org/10.1590/1981-22562018021.170054
Ramos GP, Padilha AS, Carvalho TGML, Mendes GA. A importância de exames clínicos laboratoriais no diagnóstico precoce do câncer de próstata. Revista interdisciplinar de ensino, pesquisa e extensão. 2017; 5(1): 67-78.
Santos JP, Souza AP. Considerações sobre o Câncer de Próstata: Revisão de Literatura. Id on Line Revista Multidisciplinar e de Psicologia. 2017; 10(33): 100-115. https://doi.org/10.14295/idonline.v10i33.605.
Franco RC, Souhami L. Radiotherapy and Hormone Therapy in Intermediate Risk Prostate Cancer: a Critical Review. Revista Brasileira de Cancerologia. 2015; 61(2): 155-163.
Amorim VMSL, Barros MBA, César CLG, Goldbaum M, Carandina L, Alves MCGP. Fatores associados à realização dos exames de rastreamento para o câncer de próstata: um estudo de base populacional. Cadernos de Saúde Pública. 2011; 27(2): 347-356.
Faria EF, Carvalhal GF, Dos Reis RB, Tobias-Machado M, Vieira RAC, Reis LO, et al. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels< 4.0 ng/mL. BJU International. 2012; 110(11b): E653-E657. https://doi.org/10.1111/j.1464-410X.2012.11398.x.
Lima CA, Silva AM, Kuwano AY, Rangel MRU, Macedo-Lima M. Trends in prostate cancer incidence and mortality in a mid-sized Northeastern Brazilian city. Revista da Associação Médica Brasileira. 2013; 59(1): 15-20. http://dx.doi.org/10.1590/S0104-42302013000100006.
Carvalho MHR, Carvalho SMR, Laurenti R, Payão SLM. Tendência de mortalidade de idosos por doenças crônicas no município de Marília-SP, Brasil. Epidemiologia e Serviços de Saúde. 2014; 23(2): 347-354, 2014. https://doi.org/10.5123/S1679-49742014000200016.
Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oes-terling JE, et al. Pearson, Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer, JAMA. 1997; 277(18): 1445-51. https://doi.org/10.1001/jama.1997.03540420041027.
